Analystreport

NGM Biopharmaceuticals (NYSE: NGM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.

NGM Biopharmaceuticals, Inc.  (NGM) 
Last ngm biopharmaceuticals, inc. earnings: 3/17 04:05 pm Check Earnings Report